NO20061425L - Kombinasjonen av en serotonin-reopptaksinbibitor og loxapin - Google Patents

Kombinasjonen av en serotonin-reopptaksinbibitor og loxapin

Info

Publication number
NO20061425L
NO20061425L NO20061425A NO20061425A NO20061425L NO 20061425 L NO20061425 L NO 20061425L NO 20061425 A NO20061425 A NO 20061425A NO 20061425 A NO20061425 A NO 20061425A NO 20061425 L NO20061425 L NO 20061425L
Authority
NO
Norway
Prior art keywords
loxapine
combination
serotonin reuptake
reuptake inhibitor
sri
Prior art date
Application number
NO20061425A
Other languages
English (en)
Inventor
Thomas Ivo Franciscus Cremers
Jorn Arnt
Sandra Hogg Willigers
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO20061425L publication Critical patent/NO20061425L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Den foreliggende oppfirmelse vedrører anvendelsen av en kombinasjon av loxapin og en serotonin- reopptaksinhibitor (SRI), for behandlingen av depresjon og andre affektive lidelser.
NO20061425A 2003-09-04 2006-03-29 Kombinasjonen av en serotonin-reopptaksinbibitor og loxapin NO20061425L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50080903P 2003-09-04 2003-09-04
DKPA200301270 2003-09-04
PCT/DK2004/000581 WO2005023243A1 (en) 2003-09-04 2004-09-01 The combination of a serotonin reuptake inhibitor and loxapine

Publications (1)

Publication Number Publication Date
NO20061425L true NO20061425L (no) 2006-03-29

Family

ID=34276705

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061425A NO20061425L (no) 2003-09-04 2006-03-29 Kombinasjonen av en serotonin-reopptaksinbibitor og loxapin

Country Status (8)

Country Link
EP (1) EP1670454A1 (no)
JP (1) JP2007504181A (no)
AU (1) AU2004269858A1 (no)
BR (1) BRPI0413750A (no)
CA (1) CA2537747A1 (no)
MX (1) MXPA06002504A (no)
NO (1) NO20061425L (no)
WO (1) WO2005023243A1 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
BRPI0709129A2 (pt) * 2006-03-24 2011-06-28 Wyeth Corp combinações terapêuticas para o tratamento ou prevenção de transtornos psicóticos
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
WO2008118141A2 (en) * 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
CN113242735A (zh) * 2018-09-21 2021-08-10 爱思开生物制药株式会社 使用氨基甲酸酯化合物预防、缓解或治疗并发的癫痫发作

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160898B2 (en) * 2001-12-14 2007-01-09 Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
JP2002516282A (ja) * 1998-05-22 2002-06-04 イーライ・リリー・アンド・カンパニー 難治性鬱病の処置のための組合せ治療
US20020151543A1 (en) * 1998-05-28 2002-10-17 Sepracor Inc. Compositions and methods employing R (-) fluoxetine and other active ingredients
US6572890B2 (en) * 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent

Also Published As

Publication number Publication date
CA2537747A1 (en) 2005-03-17
BRPI0413750A (pt) 2006-10-24
WO2005023243A1 (en) 2005-03-17
AU2004269858A1 (en) 2005-03-17
JP2007504181A (ja) 2007-03-01
MXPA06002504A (es) 2006-06-20
EP1670454A1 (en) 2006-06-21

Similar Documents

Publication Publication Date Title
NO20060242L (no) Kombinasjonen av en serotonin-reopptaksinhibitor og agomelatin
NO20060402L (no) 3-amino choman og 2-aminotetralinderivater
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
NO20054371L (no) Somatostatin-dopamin kimaere analoger
RS20050392A (en) Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
ATE408601T1 (de) Fredericamycin-derivate
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
NO20055741L (no) Nye kjemiske forbindelser
CY1109238T1 (el) Δισκιο περιεχον σετιριζινη και ψευδοεφεδρινη
NO20065859L (no) Bruk av IL-17 behandlingen av fertilitetsrelaterte lidelser
NO20061425L (no) Kombinasjonen av en serotonin-reopptaksinbibitor og loxapin
DE50109156D1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
NO20043952L (no) Benzofuran- og benzotiofenderivater som er nyttige ved behandling av hyperproliferative forstyrrelser
CY1110369T1 (el) Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη
ATE399557T1 (de) Selektive norepinephrin-wiederaufnahmehemmer zur behandlung von hitzewallungen
EE200400005A (et) Tablett, mis sisaldab vähemalt kahte eristatavat segmenti ning selle kasutamine
MY136367A (en) Treatment of cognitive failure
WO2004052858A3 (en) Inhibitors of monoamine uptake
CY1110368T1 (el) Συνεργιστικος συνδυασμος ο οποιος περιλαμβανει ροφλουμιλαστη και (r,r)-φορμοτερολη
HUP0204551A2 (hu) Eljárás a pikkelysömör kezelésére
DK1455770T3 (da) Anvendelse af norepinephringenoptagelsesinhibitorer til behandling af tic lidelser
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
GEP20104888B (en) Use of carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
ATE345135T1 (de) Tropan-derivate mit dopamin-wiederaufnahme-hemmer-wirkung für die behandlung von ischämischen erkrankungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application